Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olaf Penack

Showing results (111-120 of 184) with videos related to

Pageof 19
Sort By:
Frontiers in Immunology|June 30, 2026
Endothelial cell damage in patients with acute graft versus host disease receiving treatment with extracorporeal photopheresisJulia Martinez-Sanchez, Paola Charry, Ana Belén Moreno-Castaño, et al.
Journal for Immunotherapy of Cancer|April 12, 2023
Characterization of the endotheliopathy, innate-immune activation and hemostatic imbalance underlying CAR-T cell toxicities: laboratory tools for an early and differential diagnosisAna Belen Moreno-Castaño, Sara Fernández, Helena Ventosa, et al.
Frontiers in Immunology|August 15, 2020
Association of Country-Specific Socioeconomic Factors With Survival of Patients Who Experience Severe Classic Acute Graft-vs.-Host Disease After Allogeneic Hematopoietic Cell Transplantation. An Analysis From the Transplant Complications Working Party of the EBMTAndrzej Frankiewicz, Christophe Peczynski, Sebastian Giebel, et al.
The Lancet. Oncology|April 3, 2025
Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines CommitteeCharlotte E Graham, Roser Velasco, Ana Alarcon Tomas, et al.
The Lancet. Haematology|January 6, 2024
Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow TransplantationOlaf Penack, Monia Marchetti, Mahmoud Aljurf, et al.
Bone Marrow Transplantation|May 27, 2026
The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapyRaffaella Greco, Isabel Sánchez-Ortega, Antonio M Risitano, et al.
Bone Marrow Transplantation|June 3, 2026
Clonal Hematopoiesis does not influence manufacturing of Chimeric Antigen Receptor (CAR) T-CellsSimon M Krauß, Konstantin Weibl, Enrica Bach, et al.
Haematologica|June 24, 2021
Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file studyHildegard T Greinix, Dirk-Jan Eikema, Linda Koster, et al.
The European Respiratory Journal|March 14, 2024
ERS/EBMT clinical practice guidelines on treatment of pulmonary chronic graft-<i>versus</i>-host disease in adultsSaskia Bos, John Murray, Monia Marchetti, et al.
Bone Marrow Transplantation|November 24, 2022
Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experiencePeter Dreger, Udo Holtick, Marion Subklewe, et al.
Pageof 19

Showing results (111-120 of 184) with videos related to

Sort By:
Pageof 19
Frontiers in Immunology|June 30, 2026
Endothelial cell damage in patients with acute graft versus host disease receiving treatment with extracorporeal photopheresisJulia Martinez-Sanchez, Paola Charry, Ana Belén Moreno-Castaño, et al.
Journal for Immunotherapy of Cancer|April 12, 2023
Characterization of the endotheliopathy, innate-immune activation and hemostatic imbalance underlying CAR-T cell toxicities: laboratory tools for an early and differential diagnosisAna Belen Moreno-Castaño, Sara Fernández, Helena Ventosa, et al.
Frontiers in Immunology|August 15, 2020
Association of Country-Specific Socioeconomic Factors With Survival of Patients Who Experience Severe Classic Acute Graft-vs.-Host Disease After Allogeneic Hematopoietic Cell Transplantation. An Analysis From the Transplant Complications Working Party of the EBMTAndrzej Frankiewicz, Christophe Peczynski, Sebastian Giebel, et al.
The Lancet. Oncology|April 3, 2025
Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines CommitteeCharlotte E Graham, Roser Velasco, Ana Alarcon Tomas, et al.
The Lancet. Haematology|January 6, 2024
Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow TransplantationOlaf Penack, Monia Marchetti, Mahmoud Aljurf, et al.
Bone Marrow Transplantation|May 27, 2026
The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapyRaffaella Greco, Isabel Sánchez-Ortega, Antonio M Risitano, et al.
Bone Marrow Transplantation|June 3, 2026
Clonal Hematopoiesis does not influence manufacturing of Chimeric Antigen Receptor (CAR) T-CellsSimon M Krauß, Konstantin Weibl, Enrica Bach, et al.
Haematologica|June 24, 2021
Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file studyHildegard T Greinix, Dirk-Jan Eikema, Linda Koster, et al.
The European Respiratory Journal|March 14, 2024
ERS/EBMT clinical practice guidelines on treatment of pulmonary chronic graft-<i>versus</i>-host disease in adultsSaskia Bos, John Murray, Monia Marchetti, et al.
Bone Marrow Transplantation|November 24, 2022
Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experiencePeter Dreger, Udo Holtick, Marion Subklewe, et al.
Pageof 19